Jennifer Lynn Minai-Azary Purchases 40,010 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) Stock

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of the stock in a transaction dated Friday, June 6th. The shares were purchased at an average price of $0.64 per share, for a total transaction of $25,606.40. Following the completion of the transaction, the chief financial officer now owns 80,010 shares of the company's stock, valued at $51,206.40. This trade represents a 100.03% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Context Therapeutics Trading Down 3.6%

CNTX stock traded down $0.02 during trading on Friday, hitting $0.63. The company had a trading volume of 170,618 shares, compared to its average volume of 302,288. The company has a fifty day moving average price of $0.75 and a two-hundred day moving average price of $0.91. The company has a market cap of $56.46 million, a P/E ratio of -0.69 and a beta of 1.86. Context Therapeutics Inc. has a fifty-two week low of $0.49 and a fifty-two week high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). On average, analysts expect that Context Therapeutics Inc. will post -0.51 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on the company. William Blair reaffirmed an "outperform" rating on shares of Context Therapeutics in a research note on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, May 8th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $6.00.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Shay Capital LLC acquired a new position in Context Therapeutics in the fourth quarter worth $52,000. MPM Bioimpact LLC acquired a new position in Context Therapeutics in the fourth quarter worth $15,441,000. Millennium Management LLC boosted its stake in Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock worth $188,000 after purchasing an additional 34,835 shares in the last quarter. Citadel Advisors LLC acquired a new position in Context Therapeutics in the fourth quarter worth $31,000. Finally, Allostery Investments LP acquired a new position in Context Therapeutics in the fourth quarter worth $998,000. Institutional investors and hedge funds own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.